Tag: spinal muscular atrophy treatment market trends

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Spinal Muscular Atrophy Treatment Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The spinal muscular atrophy treatment market size has experienced significant growth in recent years. It is anticipated to expand from $5.1 billion in 2025 to $5.89 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.5%. Historically, this market expansion can be linked to several factors: a limited array of therapeutic options for SMA, insufficient awareness of genetic disorders, a reliance on hospital-based treatment, a sluggish adoption rate for innovative therapies, and the absence of comprehensive early diagnosis programs.

The spinal muscular atrophy treatment market size is projected to experience substantial expansion in the coming years. It will grow to $10.38 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. This anticipated growth during the projection period can be attributed to several factors, including the advancement of gene therapies, increased funding for SMA research, expanded newborn screening programs, the proliferation of specialty clinics and at-home care options, and the incorporation of digital health and remote medical solutions. Key trends anticipated for the forecast period encompass a greater acceptance of gene therapy and SMN2-modifying treatments, an intensified emphasis on early detection and newborn screening efforts, an expansion of SMA management services through homecare and specialized clinics, the formation of more multidisciplinary care teams for SMA patients, and the seamless integration of telehealth with remote patient monitoring systems.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=84911296&type=smp&name=Spinal%20Muscular%20Atrophy%20Treatment%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Spinal Muscular Atrophy Treatment Market Growth Catalysts And Demand Drivers

The increasing emphasis on gene therapy is projected to boost the expansion of the spinal muscular atrophy treatment market in the future. This medical approach entails altering an individual’s genetic makeup, specifically DNA or RNA, with the aim of treating or preventing various illnesses. The heightened attention on gene therapy stems mainly from its capacity to address or resolve the fundamental cause of genetic conditions through direct modification or replacement of defective genes, providing sustained or lasting therapeutic outcomes relative to conventional therapies. Specifically, spinal muscular atrophy treatments benefit from gene therapy, exemplified by onasemnogene abeparvovec (Zolgensma), which offers a single-dose, precise method to introduce a working copy of the SMN1 gene, substantially enhancing motor capabilities and patient life quality for those with SMA. As an illustration, in January 2024, the American Society of Gene and Cell Therapy, a US-based organization focused on gene and cell therapy, reported that the volume of gene therapies undergoing Phase III trials saw a rise of 10% in the fourth quarter of 2023 when contrasted with the preceding quarter. This represented the initial such uptick recorded since the third quarter of 2022. Consequently, the increased emphasis on gene therapy is fueling the expansion of the spinal muscular atrophy treatment market.

Spinal Muscular Atrophy Treatment Market Segment Performance And Emerging Opportunities

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

Spinal Muscular Atrophy Treatment Market Trends Shaping Long-Term Demand

Leading companies in the spinal muscular atrophy treatment market are concentrating on developing innovative formulations like survival motor neuron 2 (SMN2) splicing modifier tablets to improve motor function and slow disease progression. Survival motor neuron 2 (SMN2) splicing modifier tablets are oral medications crafted to modify the splicing of the SMN2 gene, thereby enabling the production of functional SMN protein essential for motor neuron survival. These tablets aid in treating spinal muscular atrophy (SMA) by boosting the levels of full-length SMN protein, consequently enhancing muscle function and slowing the disease’s advancement. For instance, in February 2025, Genentech, Inc., a US-based biotechnology company, secured U.S. Food and Drug Administration approval for its Evrysdi (risdiplam) tablet, recognized as the inaugural and only non-invasive SMN2 splicing modifier tablet for SMA treatment. The Evrysdi tablet provides comparable efficacy and safety to the current oral solution, with additional benefits such as storage at room temperature and simplified administration for patients aged 2 years and older who weigh more than 44 lbs (20 kgs), offering enhanced convenience and adaptability in managing the condition.

Spinal Muscular Atrophy Treatment Market Key Players: Which Companies Lead Industry Competition?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED

View The Full Spinal Muscular Atrophy Treatment Market Report:

https://thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Spinal Muscular Atrophy Treatment Market Regional Analysis And Leading Geography

North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Spinal Muscular Atrophy Treatment Market Value Expansion And Long-Term Growth Outlook

The spinal muscular atrophy treatment market has experienced significant expansion in recent years. Its value is projected to increase from $5.1 billion in 2025 to $5.89 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.5%. Historical growth was driven by factors such as the scarcity of treatment alternatives for SMA, limited public understanding of genetic conditions, a dependence on hospital-centered care, a gradual uptake of advanced therapies, and insufficient early diagnostic initiatives.

The market for spinal muscular atrophy treatments is projected to experience substantial expansion in the coming years, reaching $10.38 billion by 2030 with a compound annual growth rate of 15.2%. This upward trajectory in the forecast period is driven by the development of advanced gene therapies, increased funding for SMA research, the expansion of newborn screening initiatives, and the growth of specialized clinics and homecare services, alongside the incorporation of digital health and telemedicine solutions. Key trends influencing the period include the growing use of gene therapy and SMN2-targeting treatments, a stronger emphasis on early detection and universal newborn screening, the rise of homecare and specialty clinic-based SMA management, the development of multidisciplinary care teams for patients, and the adoption of telehealth and remote monitoring technologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Spinal Muscular Atrophy Treatment Market Growth Drivers: What Factors Are Accelerating Expansion?

The anticipated expansion of the spinal muscular atrophy treatment market is being driven by an intensified emphasis on gene therapy. This medical method entails altering a person’s genetic code—either DNA or RNA—to address or avert illnesses. This heightened attention on gene therapy stems largely from its capacity to tackle the fundamental causes of genetic disorders by directly correcting or substituting defective genes, thereby providing enduring or permanent therapeutic benefits that surpass those of conventional approaches. Treatments for spinal muscular atrophy, like onasemnogene abeparvovec (Zolgensma), effectively leverage gene therapy through a single-dose, precision-focused strategy that introduces a working version of the SMN1 gene, substantially enhancing motor abilities and life quality for SMA patients. As an example, reports from the American Society of Gene and Cell Therapy, a US-based entity dedicated to gene and cell therapy, indicate that by January 2024, there was a 10% rise in Phase III gene therapy trials during the fourth quarter of 2023 compared to the prior quarter—the first such uptick observed since the third quarter of 2022. Consequently, this increasing concentration on gene therapy is fueling the momentum behind the spinal muscular atrophy treatment market.

Spinal Muscular Atrophy Treatment Market Segment Analysis Highlighting Growth Areas

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

Spinal Muscular Atrophy Treatment Market Trends: What Is Shaping Future Industry Growth?

Leading market players in the spinal muscular atrophy treatment sector are concentrating on creating advanced formulations, such as survival motor neuron 2 (SMN2) splicing modifier tablets, aimed at boosting motor function and decelerating disease advancement. These tablets, which are taken orally, work by altering the splicing of the SMN2 gene to promote the production of functional SMN protein, essential for preserving motor neurons. By elevating levels of full-length SMN protein, they assist in treating spinal muscular atrophy (SMA), leading to enhanced muscle function and a slower progression of the condition. A notable example occurred in February 2025 when Genentech, Inc., a biotechnology firm based in the United States, secured U.S. Food and Drug Administration approval for its Evrysdi (risdiplam) tablet. This represents the first non-invasive SMN2 splicing modifier tablet specifically designed for SMA management. The Evrysdi tablet delivers effectiveness and safety comparable to the current oral solution, while offering extra advantages like the ability to be stored at room temperature and easier administration for patients aged 2 years and older weighing over 44 lbs (20 kgs), thereby improving convenience and adaptability in disease control.

Spinal Muscular Atrophy Treatment Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED

Access The Complete Spinal Muscular Atrophy Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Spinal Muscular Atrophy Treatment Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Spinal Muscular Atrophy Treatment Market Value Expansion And Long-Term Growth Outlook

The spinal muscular atrophy treatment market has experienced significant expansion in recent years. Its value is projected to increase from $5.1 billion in 2025 to $5.89 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.5%. Historical growth was driven by factors such as the scarcity of treatment alternatives for SMA, limited public understanding of genetic conditions, a dependence on hospital-centered care, a gradual uptake of advanced therapies, and insufficient early diagnostic initiatives.

The market for spinal muscular atrophy treatments is projected to experience substantial expansion in the coming years, reaching $10.38 billion by 2030 with a compound annual growth rate of 15.2%. This upward trajectory in the forecast period is driven by the development of advanced gene therapies, increased funding for SMA research, the expansion of newborn screening initiatives, and the growth of specialized clinics and homecare services, alongside the incorporation of digital health and telemedicine solutions. Key trends influencing the period include the growing use of gene therapy and SMN2-targeting treatments, a stronger emphasis on early detection and universal newborn screening, the rise of homecare and specialty clinic-based SMA management, the development of multidisciplinary care teams for patients, and the adoption of telehealth and remote monitoring technologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Spinal Muscular Atrophy Treatment Market Growth Drivers: What Factors Are Accelerating Expansion?

The anticipated expansion of the spinal muscular atrophy treatment market is being driven by an intensified emphasis on gene therapy. This medical method entails altering a person’s genetic code—either DNA or RNA—to address or avert illnesses. This heightened attention on gene therapy stems largely from its capacity to tackle the fundamental causes of genetic disorders by directly correcting or substituting defective genes, thereby providing enduring or permanent therapeutic benefits that surpass those of conventional approaches. Treatments for spinal muscular atrophy, like onasemnogene abeparvovec (Zolgensma), effectively leverage gene therapy through a single-dose, precision-focused strategy that introduces a working version of the SMN1 gene, substantially enhancing motor abilities and life quality for SMA patients. As an example, reports from the American Society of Gene and Cell Therapy, a US-based entity dedicated to gene and cell therapy, indicate that by January 2024, there was a 10% rise in Phase III gene therapy trials during the fourth quarter of 2023 compared to the prior quarter—the first such uptick observed since the third quarter of 2022. Consequently, this increasing concentration on gene therapy is fueling the momentum behind the spinal muscular atrophy treatment market.

Spinal Muscular Atrophy Treatment Market Segment Analysis Highlighting Growth Areas

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

Spinal Muscular Atrophy Treatment Market Trends: What Is Shaping Future Industry Growth?

Leading market players in the spinal muscular atrophy treatment sector are concentrating on creating advanced formulations, such as survival motor neuron 2 (SMN2) splicing modifier tablets, aimed at boosting motor function and decelerating disease advancement. These tablets, which are taken orally, work by altering the splicing of the SMN2 gene to promote the production of functional SMN protein, essential for preserving motor neurons. By elevating levels of full-length SMN protein, they assist in treating spinal muscular atrophy (SMA), leading to enhanced muscle function and a slower progression of the condition. A notable example occurred in February 2025 when Genentech, Inc., a biotechnology firm based in the United States, secured U.S. Food and Drug Administration approval for its Evrysdi (risdiplam) tablet. This represents the first non-invasive SMN2 splicing modifier tablet specifically designed for SMA management. The Evrysdi tablet delivers effectiveness and safety comparable to the current oral solution, while offering extra advantages like the ability to be stored at room temperature and easier administration for patients aged 2 years and older weighing over 44 lbs (20 kgs), thereby improving convenience and adaptability in disease control.

Spinal Muscular Atrophy Treatment Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED

Access The Complete Spinal Muscular Atrophy Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Spinal Muscular Atrophy Treatment Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Spinal Muscular Atrophy Treatment Market Over The Forecast Period?

The market size for spinal muscular atrophy treatments has experienced rapid expansion in recent years. It is projected to grow from $5.1 billion in 2025 to $5.89 billion in 2026, at a compound annual growth rate (CAGR) of 15.5%. Factors contributing to the market’s historical growth include limited therapeutic options for SMA, insufficient awareness of genetic disorders, a reliance on hospital-based treatment, slow adoption of innovative therapies, and a lack of early diagnosis programs.

The spinal muscular atrophy treatment market is projected to experience swift expansion over the coming years. It is anticipated to reach a size of $10.38 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.2%. This growth during the forecast period can be ascribed to several factors, including the emergence of advanced gene therapies, increased investment in SMA research, expanding newborn screening programs, the proliferation of specialized clinics and homecare services, and the incorporation of digital health and telemedicine technologies. Key trends anticipated within the same period encompass a greater uptake of gene therapy and SMN2 modifying treatments, an intensified emphasis on early diagnosis and newborn screening efforts, the expansion of homecare and specialty clinic-based SMA management approaches, the broadening of multidisciplinary care teams dedicated to SMA patients, and the seamless integration of telehealth and remote patient monitoring systems.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp

What Core Drivers Are Transforming The Spinal Muscular Atrophy Treatment Market?

The increasing attention on gene therapy is anticipated to drive the expansion of the spinal muscular atrophy treatment market in the future. Gene therapy is defined as a medical approach involving the alteration of an individual’s genetic material, specifically DNA or RNA, to address or prevent illnesses. This heightened emphasis on gene therapy largely stems from its capability to address or resolve the underlying cause of genetic conditions through direct modification or replacement of defective genes, thereby providing lasting or permanent therapeutic outcomes compared to conventional therapies. Spinal muscular atrophy treatments leverage gene therapy, exemplified by onasemnogene abeparvovec (Zolgensma), which offers a singular, targeted method to deliver a working copy of the SMN1 gene, substantially enhancing motor function and patient quality of life for those with SMA. As an illustration, in January 2024, the American Society of Gene and Cell Therapy, a US-based organization dedicated to gene and cell therapy, reported a 10% rise in gene therapies undergoing Phase III trials during the fourth quarter of 2023 relative to the preceding quarter. This represented the first such increase witnessed since the third quarter of 2022. Consequently, the intensified focus on gene therapy is propelling the growth of the spinal muscular atrophy treatment market.

What Segment Types Are Included In The Spinal Muscular Atrophy Treatment Market Analysis?

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

Which Trends Are Guiding The Development Of The Spinal Muscular Atrophy Treatment Market?

Companies prominent in the spinal muscular atrophy treatment market are prioritizing the creation of novel formulations, including survival motor neuron 2 (SMN2) splicing modifier tablets, aimed at improving motor capabilities and decelerating disease progression. These SMN2 splicing modifier tablets are orally administered drugs formulated to modify the splicing of the SMN2 gene, thereby facilitating the generation of functional SMN protein, which is essential for the survival of motor neurons. By elevating the concentrations of full-length SMN protein, these tablets contribute to the treatment of spinal muscular atrophy (SMA), leading to enhanced muscle function and a reduction in the rate of disease progression. An example of this trend is Genentech, Inc., a US-based biotechnology company, which in February 2025 secured U.S. Food and Drug Administration approval for its Evrysdi (risdiplam) tablet, notable as the inaugural and sole non-invasive SMN2 splicing modifier tablet indicated for SMA treatment. The Evrysdi tablet demonstrates similar effectiveness and safety profiles to existing oral solutions, while offering additional advantages like storage at room temperature and streamlined administration for patients 2 years and older weighing over 44 lbs (20 kgs), ultimately delivering increased convenience and adaptability in managing the condition.

Which Organizations Are Operating Within The Spinal Muscular Atrophy Treatment Market?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED

Access The Complete Spinal Muscular Atrophy Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report

Which Region Is The Primary Market For The Spinal Muscular Atrophy Treatment Market?

North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Spinal Muscular Atrophy Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Treatment Market 2026, By The Business Research Company

Spinal Surgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-global-market-report

Cerebrospinal Fluid Management Csf Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cerebrospinal-fluid-management-csf-devices-and-equipment-global-market-report

Spinal Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/spinal-imaging-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Spinal Muscular Atrophy Treatment Market Between 2026 And 2030?

The spinal muscular atrophy treatment market has experienced substantial expansion in its size over recent years. This market is projected to expand from $5.1 billion in 2025 to reach $5.89 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.5%. Historically, this growth has been linked to factors such as restricted therapeutic choices for SMA, insufficient public understanding of genetic conditions, a dependence on hospital-centric care, the gradual integration of novel treatments, and the absence of comprehensive early diagnosis initiatives.

The spinal muscular atrophy treatment market is projected to experience swift expansion over the coming years. By 2030, its size is predicted to reach $10.38 billion, demonstrating a compound annual growth rate (CAGR) of 15.2%. This anticipated growth during the forecast period is driven by factors such as the advancement of sophisticated gene therapies, increased funding for SMA research, expanded newborn screening programs, the proliferation of specialized clinics and homecare options, and the incorporation of digital health and telemedicine technologies. Key trends foreseen in this period encompass the growing acceptance of gene therapy and SMN2-modifying therapies, a heightened emphasis on prompt diagnosis and newborn screening protocols, an increase in homecare and specialized clinic-based SMA management, the enlargement of multidisciplinary care teams assisting SMA patients, and the widespread adoption of telehealth alongside remote patient monitoring.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp

What Key Drivers Are Influencing The Growth Of The Spinal Muscular Atrophy Treatment Market?

The spinal muscular atrophy treatment market is anticipated to expand due to increasing attention on gene therapy. This medical technique, gene therapy, entails altering an individual’s genetic material (DNA or RNA) for disease treatment or prevention. The heightened interest in gene therapy stems mainly from its capacity to address the fundamental cause of genetic disorders by directly adjusting or substituting defective genes, providing sustained or lasting therapeutic outcomes unlike conventional therapies. Treatments for spinal muscular atrophy benefit from gene therapy, exemplified by onasemnogene abeparvovec (Zolgensma), which offers a single, targeted method to deliver a working SMN1 gene copy, substantially enhancing motor function and patient quality of life for those with SMA. As an illustration, the American Society of Gene and Cell Therapy, a US-based entity, reported in January 2024 that gene therapies undergoing Phase III trials saw a 10% rise in the fourth quarter of 2023 compared to the previous quarter, marking the initial such increase since the third quarter of 2022. Consequently, the increasing emphasis on gene therapy is a key driver for the expansion of the spinal muscular atrophy treatment market.

Which Market Segments Are Examined In The Spinal Muscular Atrophy Treatment Market Study?

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

Which Trends Are Influencing The Spinal Muscular Atrophy Treatment Market?

Major companies operating in the spinal muscular atrophy treatment market are concentrating on developing innovative formulations, such as survival motor neuron 2 (SMN2) splicing modifier tablets, to enhance motor function and slow the advancement of the disease. These survival motor neuron 2 (SMN2) splicing modifier tablets are oral medications engineered to alter the splicing of the SMN2 gene, which facilitates the production of functional SMN protein crucial for motor neuron survival. By increasing the levels of full-length SMN protein, these tablets contribute to treating spinal muscular atrophy (SMA), thereby improving muscle function and decelerating disease progression. For example, in February 2025, Genentech, Inc., a US-based biotechnology company, obtained U.S. Food and Drug Administration approval for its Evrysdi (risdiplam) tablet, which is the first and only non-invasive SMN2 splicing modifier tablet approved for the treatment of SMA. The Evrysdi tablet provides comparable efficacy and safety to the existing oral solution, along with added benefits such as room-temperature storage and simplified administration for patients aged 2 years and older who weigh more than 44 lbs (20 kgs), offering greater convenience and flexibility in managing the condition.

Who Are The Primary Competitors In The Spinal Muscular Atrophy Treatment Market?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED

Read the full spinal muscular atrophy treatment market report here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Spinal Muscular Atrophy Treatment Market?

North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Spinal Muscular Atrophy Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24714&type=smp

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Treatment Market 2026, By The Business Research Company

Spinal Surgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-global-market-report

Cerebrospinal Fluid Management Csf Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cerebrospinal-fluid-management-csf-devices-and-equipment-global-market-report

Spinal Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/spinal-imaging-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the spinal muscular atrophy treatment market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Spinal Muscular Atrophy Treatment Market show for the 2026–2030 period?

The spinal muscular atrophy treatment market size has seen rapid expansion in recent years. It is projected to increase from $5.1 billion in 2025 to $5.89 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.5%. The historical growth within this market can be attributed to factors such as limited therapeutic options for SMA, low awareness regarding genetic disorders, a reliance on hospital-based treatment, the slow adoption of innovative therapies, and an absence of early diagnosis programs.

The spinal muscular atrophy treatment market is anticipated to experience substantial growth in the coming years, with projections indicating it will reach $10.38 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.2%. This expected growth throughout the forecast period can be attributed to several factors, including the development of advanced gene therapies, increased investment in SMA research, the expansion of newborn screening initiatives, the rise of specialty clinics and homecare services, and the integration of digital health and telemedicine solutions. Key trends during this period are expected to include the rising adoption of gene therapy and SMN2 modifying treatments, a heightened focus on early diagnosis and newborn screening programs, the growth of homecare and specialty clinic-based SMA management, the expansion of multidisciplinary care teams for SMA patients, and the broader integration of telehealth and remote patient monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp

What Drivers Are Shaping The Development Of The Spinal Muscular Atrophy Treatment Market?

An increasing emphasis on gene therapy is projected to drive the expansion of the spinal muscular atrophy treatment market in the future. This medical technique entails altering an individual’s DNA or RNA to address or avert illnesses. The heightened attention to gene therapy stems largely from its capacity to tackle or resolve the underlying cause of genetic conditions through direct modification or replacement of defective genes, thereby providing enduring or permanent therapeutic outcomes versus conventional therapies. Specific spinal muscular atrophy treatments, like onasemnogene abeparvovec (Zolgensma), leverage gene therapy by offering a single-dose, targeted solution that introduces a working copy of the SMN1 gene, leading to substantial improvements in motor function and overall quality of life for patients with SMA. As an illustration, data from January 2024, released by the American Society of Gene and Cell Therapy, a US-based body dedicated to gene and cell therapy, indicated a 10% rise in the number of gene therapies undergoing Phase III trials during the fourth quarter of 2023 relative to the quarter prior. This marked the initial surge of this kind since the third quarter of 2022. Consequently, the increasing focus on gene therapy is fueling the growth of the spinal muscular atrophy treatment market.

Which Segments Are Contributing To The Growth Of The Spinal Muscular Atrophy Treatment Market?

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

What Long-Term Trends Are Expected To Shape The Future Of The Spinal Muscular Atrophy Treatment Market?

Companies operating within the spinal muscular atrophy treatment market are primarily concentrating on developing innovative pharmaceutical compositions, such as survival motor neuron 2 (SMN2) splicing modifier tablets, to improve motor function and retard the advancement of the disease. These oral medications, survival motor neuron 2 (SMN2) splicing modifier tablets, are engineered to alter the splicing of the SMN2 gene, enabling the generation of functional SMN protein crucial for motor neuron survival. By elevating the levels of full-length SMN protein, these tablets aid in treating spinal muscular atrophy (SMA), subsequently enhancing muscle function and slowing the disease’s progression. For example, in February 2025, Genentech, Inc., a US-based biotechnology company, secured U.S. Food and Drug Administration approval for its Evrysdi (risdiplam) tablet, which stands as the inaugural and sole non-invasive SMN2 splicing modifier tablet for SMA treatment. The Evrysdi tablet delivers comparable effectiveness and safety to the existing oral solution, while also offering additional benefits like room-temperature storage and simpler administration for patients aged 2 years and older who weigh more than 44 lbs (20 kgs), thereby increasing convenience and adaptability in managing the illness.

Who Are The Primary Competitors In The Global Spinal Muscular Atrophy Treatment Market?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Spinal Muscular Atrophy Treatment Market?

North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Spinal Muscular Atrophy Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24714&type=smp

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Treatment Market 2026, By The Business Research Company

Spinal Surgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-global-market-report

Cerebrospinal Fluid Management Csf Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cerebrospinal-fluid-management-csf-devices-and-equipment-global-market-report

Spinal Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/spinal-imaging-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Spinal Muscular Atrophy Treatment Sector?

The market for treatment of spinal muscular atrophy has been developing at an increased rate in the past few years. It is projected to expand from a worth of $4.41 billion in 2024 to a value of $5.1 billion in 2025, with a compound annual growth rate (CAGR) of 15.7%. This considerable growth in the historic phase can be accredited to factors such as a rise in the cases of spinal muscular atrophy, increasing approval for new gene therapy methods, growing cognizance for early detection and treatment, increment in research and development ventures, and the rising provision of newborn screening practices.

Rapid expansion is anticipated for the spinal muscular atrophy treatment market, with forecasts indicating it will swell to $9.02 billion by 2029, growing at a compound annual growth rate (CAGR) of 15.3%. Factors contributing to this growth during the forecast period include the escalating prevalence of spinal muscular atrophy, the surge in approved, innovative gene therapies, and heightened awareness for early diagnosis and treatment. Additionally, increased investment in research and development coupled with wider reach of newborn screening programs also play a part. Future trends include gene therapy advancement, the inclusion of personalized medicine methods, technologically advanced development of oral treatments, enhancement in newborn screening approaches, and progress in combined therapeutic methodologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp

What Forces Are Driving The Growth Of The Spinal Muscular Atrophy Treatment Market?

As interest in gene therapy intensifies, the spinal muscular atrophy treatment market is projected to expand. Gene therapy, a medical method that manipulates a person’s genetic material (either DNA or RNA) to treat or prevent diseases, is increasingly seen as a potential way to directly modify or replace defective genes. This can address the root cause of genetic disorders, offering more long-lasting or permanent therapeutic effects as opposed to conventional treatments. Gene therapy techniques like onasemnogene abeparvovec (Zolgensma) are beneficial for spinal muscular atrophy treatments, providing a one-time, targeted strategy that delivers a functional copy of the SMN1 gene. This significantly enhances motor function and life quality for individuals with SMA. Notably, the American Society of Gene and Cell Therapy reported in January 2024 that the number of gene therapies in Phase III trials rose by 10% in the last quarter of 2023 from the previous quarter, marking the first increase since the third quarter of 2022. Hence, the escalating attention on gene therapy is aiding the growth of the spinal muscular atrophy treatment market.

How Is The Spinal Muscular Atrophy Treatment Industry Segmented Across Key Parameters?

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

What Notable Trends Are Shaping The Direction Of The Spinal Muscular Atrophy Treatment Market?

Prominent businesses in the spinal muscular atrophy treatment market are concentrating their efforts on producing innovative versions like survival motor neuron 2 (SMN2) splicing modifier tablets. These potent new drugs are designed to amplify motor function and slow the advancement of the disease. Specifically designed for oral consumption, these SMN2 splicing modifier tablets alter the SMN2 gene’s splicing, thus producing functional SMN protein which is a crucial component for the survival of motor neurons. The tablets play a significant role in treating spinal muscular atrophy (SMA) by boosting the amounts of full-length SMN protein, leading to an improvement in muscle function and stabilizing the progression of the ailment. In February 2025, an example of this was when Genentech, Inc., a biotechnology company based in the United States, was granted approval for its Evrysdi (risdiplam) tablet by the U.S. Food and Drug Administration. This was the first and sole non-invasive SMN2 splicing modifier tablet introduced for treating SMA. The Evrysdi tablet is as effective and safe as the current oral solution, plus it brings added benefits such as storage at room temperature and simplified usage for individuals aged two years or over who weigh above 44 lbs (20 kgs), providing increased convenience and adaptability in the management of the disease.

Which Companies Currently Dominate The Competitive Landscape In The Spinal Muscular Atrophy Treatment Industry?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., BIOCAD INDIA PRIVATE LIMITED, Cytokinetics Incorporated, Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc, NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Alcyone Therapeutics Inc., Vybion Inc., Apteeus SAS, Biophytis SA, Ractigen Therapeutics.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report

Which Geographic Regions Are Driving Demand In The Spinal Muscular Atrophy Treatment Market?

North America was the largest region in the spinal muscular atrophy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24714&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Spinal Muscular Atrophy Treatment Sector?

The market for treatment of spinal muscular atrophy has been developing at an increased rate in the past few years. It is projected to expand from a worth of $4.41 billion in 2024 to a value of $5.1 billion in 2025, with a compound annual growth rate (CAGR) of 15.7%. This considerable growth in the historic phase can be accredited to factors such as a rise in the cases of spinal muscular atrophy, increasing approval for new gene therapy methods, growing cognizance for early detection and treatment, increment in research and development ventures, and the rising provision of newborn screening practices.

Rapid expansion is anticipated for the spinal muscular atrophy treatment market, with forecasts indicating it will swell to $9.02 billion by 2029, growing at a compound annual growth rate (CAGR) of 15.3%. Factors contributing to this growth during the forecast period include the escalating prevalence of spinal muscular atrophy, the surge in approved, innovative gene therapies, and heightened awareness for early diagnosis and treatment. Additionally, increased investment in research and development coupled with wider reach of newborn screening programs also play a part. Future trends include gene therapy advancement, the inclusion of personalized medicine methods, technologically advanced development of oral treatments, enhancement in newborn screening approaches, and progress in combined therapeutic methodologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp

What Forces Are Driving The Growth Of The Spinal Muscular Atrophy Treatment Market?

As interest in gene therapy intensifies, the spinal muscular atrophy treatment market is projected to expand. Gene therapy, a medical method that manipulates a person’s genetic material (either DNA or RNA) to treat or prevent diseases, is increasingly seen as a potential way to directly modify or replace defective genes. This can address the root cause of genetic disorders, offering more long-lasting or permanent therapeutic effects as opposed to conventional treatments. Gene therapy techniques like onasemnogene abeparvovec (Zolgensma) are beneficial for spinal muscular atrophy treatments, providing a one-time, targeted strategy that delivers a functional copy of the SMN1 gene. This significantly enhances motor function and life quality for individuals with SMA. Notably, the American Society of Gene and Cell Therapy reported in January 2024 that the number of gene therapies in Phase III trials rose by 10% in the last quarter of 2023 from the previous quarter, marking the first increase since the third quarter of 2022. Hence, the escalating attention on gene therapy is aiding the growth of the spinal muscular atrophy treatment market.

How Is The Spinal Muscular Atrophy Treatment Industry Segmented Across Key Parameters?

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

What Notable Trends Are Shaping The Direction Of The Spinal Muscular Atrophy Treatment Market?

Prominent businesses in the spinal muscular atrophy treatment market are concentrating their efforts on producing innovative versions like survival motor neuron 2 (SMN2) splicing modifier tablets. These potent new drugs are designed to amplify motor function and slow the advancement of the disease. Specifically designed for oral consumption, these SMN2 splicing modifier tablets alter the SMN2 gene’s splicing, thus producing functional SMN protein which is a crucial component for the survival of motor neurons. The tablets play a significant role in treating spinal muscular atrophy (SMA) by boosting the amounts of full-length SMN protein, leading to an improvement in muscle function and stabilizing the progression of the ailment. In February 2025, an example of this was when Genentech, Inc., a biotechnology company based in the United States, was granted approval for its Evrysdi (risdiplam) tablet by the U.S. Food and Drug Administration. This was the first and sole non-invasive SMN2 splicing modifier tablet introduced for treating SMA. The Evrysdi tablet is as effective and safe as the current oral solution, plus it brings added benefits such as storage at room temperature and simplified usage for individuals aged two years or over who weigh above 44 lbs (20 kgs), providing increased convenience and adaptability in the management of the disease.

Which Companies Currently Dominate The Competitive Landscape In The Spinal Muscular Atrophy Treatment Industry?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., BIOCAD INDIA PRIVATE LIMITED, Cytokinetics Incorporated, Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc, NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Alcyone Therapeutics Inc., Vybion Inc., Apteeus SAS, Biophytis SA, Ractigen Therapeutics.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report

Which Geographic Regions Are Driving Demand In The Spinal Muscular Atrophy Treatment Market?

North America was the largest region in the spinal muscular atrophy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24714&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Spinal Muscular Atrophy Treatment Sector?

The market for treatment of spinal muscular atrophy has been developing at an increased rate in the past few years. It is projected to expand from a worth of $4.41 billion in 2024 to a value of $5.1 billion in 2025, with a compound annual growth rate (CAGR) of 15.7%. This considerable growth in the historic phase can be accredited to factors such as a rise in the cases of spinal muscular atrophy, increasing approval for new gene therapy methods, growing cognizance for early detection and treatment, increment in research and development ventures, and the rising provision of newborn screening practices.

Rapid expansion is anticipated for the spinal muscular atrophy treatment market, with forecasts indicating it will swell to $9.02 billion by 2029, growing at a compound annual growth rate (CAGR) of 15.3%. Factors contributing to this growth during the forecast period include the escalating prevalence of spinal muscular atrophy, the surge in approved, innovative gene therapies, and heightened awareness for early diagnosis and treatment. Additionally, increased investment in research and development coupled with wider reach of newborn screening programs also play a part. Future trends include gene therapy advancement, the inclusion of personalized medicine methods, technologically advanced development of oral treatments, enhancement in newborn screening approaches, and progress in combined therapeutic methodologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp

What Forces Are Driving The Growth Of The Spinal Muscular Atrophy Treatment Market?

As interest in gene therapy intensifies, the spinal muscular atrophy treatment market is projected to expand. Gene therapy, a medical method that manipulates a person’s genetic material (either DNA or RNA) to treat or prevent diseases, is increasingly seen as a potential way to directly modify or replace defective genes. This can address the root cause of genetic disorders, offering more long-lasting or permanent therapeutic effects as opposed to conventional treatments. Gene therapy techniques like onasemnogene abeparvovec (Zolgensma) are beneficial for spinal muscular atrophy treatments, providing a one-time, targeted strategy that delivers a functional copy of the SMN1 gene. This significantly enhances motor function and life quality for individuals with SMA. Notably, the American Society of Gene and Cell Therapy reported in January 2024 that the number of gene therapies in Phase III trials rose by 10% in the last quarter of 2023 from the previous quarter, marking the first increase since the third quarter of 2022. Hence, the escalating attention on gene therapy is aiding the growth of the spinal muscular atrophy treatment market.

How Is The Spinal Muscular Atrophy Treatment Industry Segmented Across Key Parameters?

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

What Notable Trends Are Shaping The Direction Of The Spinal Muscular Atrophy Treatment Market?

Prominent businesses in the spinal muscular atrophy treatment market are concentrating their efforts on producing innovative versions like survival motor neuron 2 (SMN2) splicing modifier tablets. These potent new drugs are designed to amplify motor function and slow the advancement of the disease. Specifically designed for oral consumption, these SMN2 splicing modifier tablets alter the SMN2 gene’s splicing, thus producing functional SMN protein which is a crucial component for the survival of motor neurons. The tablets play a significant role in treating spinal muscular atrophy (SMA) by boosting the amounts of full-length SMN protein, leading to an improvement in muscle function and stabilizing the progression of the ailment. In February 2025, an example of this was when Genentech, Inc., a biotechnology company based in the United States, was granted approval for its Evrysdi (risdiplam) tablet by the U.S. Food and Drug Administration. This was the first and sole non-invasive SMN2 splicing modifier tablet introduced for treating SMA. The Evrysdi tablet is as effective and safe as the current oral solution, plus it brings added benefits such as storage at room temperature and simplified usage for individuals aged two years or over who weigh above 44 lbs (20 kgs), providing increased convenience and adaptability in the management of the disease.

Which Companies Currently Dominate The Competitive Landscape In The Spinal Muscular Atrophy Treatment Industry?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., BIOCAD INDIA PRIVATE LIMITED, Cytokinetics Incorporated, Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc, NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Alcyone Therapeutics Inc., Vybion Inc., Apteeus SAS, Biophytis SA, Ractigen Therapeutics.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report

Which Geographic Regions Are Driving Demand In The Spinal Muscular Atrophy Treatment Market?

North America was the largest region in the spinal muscular atrophy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24714&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Spinal Muscular Atrophy Treatment Market Grown from 2024 to 2025?

The treatment market for spinal muscular atrophy has seen a rapid expansion in recent years. From $4.41 billion in 2024, it is projected to increase to $5.1 billion in 2025 with a compound annual growth rate (CAGR) of 15.7%. This aggressive growth in the past years can be traced back to factors such as the increasing instances of spinal muscular atrophy, the rising number of authorised innovative gene therapies, escalated consciousness about early detection and treatment, growing investment in research and development, and the increasing accessibility of newborn screening programs.

What Growth Rate Is Anticipated for the Spinal Muscular Atrophy Treatment Market in the Coming Years?

The market for spinal muscular atrophy treatments is predicted to experience rapid expansion in the forthcoming years. It is anticipated to reach $9.02 billion in 2029, with a compound annual growth rate (CAGR) of 15.3%. This growth in the forecast period is attributed to a variety of factors including the growing incidents of spinal muscular atrophy, an increase in approved innovative gene therapies, increased awareness surrounding early diagnosis and treatment, a surge in investment in research and development, and an expanding availability of newborn screening programs. Key trends anticipated in the forecast period encompass advancements in gene therapy techniques, the incorporation of personalized medicine strategies, the technological development of oral therapies, advancements in newborn screening programs, and continued development in combination therapy tactics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp

Who Are the Leading Companies in the Spinal Muscular Atrophy Treatment Market?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., BIOCAD INDIA PRIVATE LIMITED, Cytokinetics Incorporated, Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc, NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Alcyone Therapeutics Inc., Vybion Inc., Apteeus SAS, Biophytis SA, Ractigen Therapeutics.

What Are the Key Drivers of the Spinal Muscular Atrophy Treatment Market?

The spinal muscular atrophy treatment market is poised for growth, largely due to the rising emphasis on gene therapy. This medical technique, which alters a person’s genetic makeup using DNA or RNA, is harnessed to treat or prevent illnesses. The escalating interest in gene therapy primarily hinges on its unprecedented ability to address the fundamental causes of genetic disorders by modifying or replacing defective genes. This results in more enduring or even permanent curative outcomes compared to conventional methods. Treatments for spinal muscular atrophy are particularly compatible with gene therapy, with onasemnogene abeparvovec (Zolgensma) standing out as a once-only, targeted protocol that delivers a working version of the SMN1 gene thus boosting motor function and life quality in SMA patients. As an illustration, the American Society of Gene and Cell Therapy reported in January 2024 that Phase III trials of gene therapies in the US saw a 10% increment in the last quarter of 2023, the first such surge since Q3 2022. Consequently, the mounting attention on gene therapy is fueling the expansion of the spinal muscular atrophy treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24714&type=smp

What Are the Key Market Segments in the Spinal Muscular Atrophy Treatment Industry?

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

What Are the Latest Trends in the Spinal Muscular Atrophy Treatment Market?

Prominent players in the market for spinal muscular atrophy treatment are geared towards the creation of novel formulations such as survival motor neuron 2 (SMN2) splicing modifier tablets. This is with the aim of enhancing motor function and slowing the disease’s progression. The survival motor neuron 2 (SMN2) splicing modifier tablets are orally taken medication, made to change the splicing of the SMN2 gene. This adjustment allows the creation of operational SMN protein essential for the survival of motor neurons. These tablets aid in the treatment of spinal muscular atrophy (SMA) by augmenting levels of the full-length SMN protein, resulting in an improvement in muscle function and deceleration of disease progression. For example, in February 2025, Genentech, Inc., a US biotech firm, got the green light from the U.S. Food and Drug Administration for its Evrysdi (risdiplam) tablet. This is the first and only non-invasive SMN2 splicing modifier tablet uniquely formulated for SMA treatment. The Evrysdi tablet equates to the already existing oral solution in terms of effectiveness and safety, but has added advantages like being able to be stored at room temperature and easy administration for patients who are 2 years and above and weigh more than 20 kgs (44 lbs). This offers more convenience and adaptability in managing the disease.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report

What Are the Key Regional Markets in the Spinal Muscular Atrophy Treatment Industry?

North America was the largest region in the spinal muscular atrophy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24714

This Report Delivers Insight On:

1. How big is the spinal muscular atrophy treatment market, and how is it changing globally?

2. Who are the major companies in the spinal muscular atrophy treatment market, and how are they performing?

3. What are the key opportunities and risks in the spinal muscular atrophy treatment market right now?

4. Which products or customer segments are growing the most in the spinal muscular atrophy treatment market?

5. What factors are helping or slowing down the growth of the spinal muscular atrophy treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model